People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Marea Therapeutics, Inc. | — | Biotechnology | Series C | $65.4M | $595.9M | 2024 |
Mark Joing at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Joing on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Chris Garabedian | 1 | 8 |
| Aaron Royston | 1 | 7 |
| Maha Katabi | 1 | 6 |
| Josh Lehrer | 1 | 2 |
| Jeff Tong | 1 | 2 |
| Ted Love | 1 | 2 |
| Antoine Boulanger | 1 | 1 |
| Christine Garrett | 1 | 1 |
| Ethan Weiss | 1 | 1 |
| Caitlin Murray | 1 | 1 |
| Jung Choi | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.